CN101319008B - Polypeptide having specific combination with neoplasm metastasis cell and uses thereof - Google Patents

Polypeptide having specific combination with neoplasm metastasis cell and uses thereof Download PDF

Info

Publication number
CN101319008B
CN101319008B CN2008101286335A CN200810128633A CN101319008B CN 101319008 B CN101319008 B CN 101319008B CN 2008101286335 A CN2008101286335 A CN 2008101286335A CN 200810128633 A CN200810128633 A CN 200810128633A CN 101319008 B CN101319008 B CN 101319008B
Authority
CN
China
Prior art keywords
pro
phage
cell
polypeptide
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008101286335A
Other languages
Chinese (zh)
Other versions
CN101319008A (en
Inventor
张翠竹
张宏恺
李鑫
曹又佳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nankai University
Original Assignee
Nankai University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nankai University filed Critical Nankai University
Priority to CN2008101286335A priority Critical patent/CN101319008B/en
Publication of CN101319008A publication Critical patent/CN101319008A/en
Application granted granted Critical
Publication of CN101319008B publication Critical patent/CN101319008B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Abstract

The invention relates to polypeptide combined with the specificity of tumor metastasis cells, as well as an application thereof. The amino acid sequence of the polypeptide combined with the surface antigen specificity of the tumor metastasis cells is Leu-Pro-Trp-Lys-Glu-Pro-Tyr-Tyr-Leu-Met-Pro-Pro. The polypeptide has the characteristics that the polypeptide is combined with the specificity of the tumor metastasis cells and inhibits the movement of the tumor metastasis cells. Therefore, the polypeptide can be used as a diagnosis marker for tumor metastasis, and can be applied to develop precursors for tumor metastasis inhibiting medicine.

Description

With metastases cell-specific bonded polypeptide and application thereof
Technical field
The invention belongs to biotechnology and biological medicine technology field, relate to utilize display technique of bacteriophage screening can with metastases cell-surface antigens specificity bonded polypeptide, specifically, be application tumor in situ and metastases clone differential screening 12 peptide phage display libraries at random, obtaining can be as special 12 peptide sequence of metastases mark.
Background technology
Tumour cell is invaded lymphatic vessel, blood vessel or body cavity from original position, migrate to its place and continued growth, forms the tumour with the primary tumor same-type, be called transfer [Yang Guanghua etc. " pathology " (the 5th edition), the People's Health Publisher, calendar year 2001, P87).
Find the improper expression of the various molecules of tumor cell surface from molecular level, for transfer and the great significance of differentiating tumour, VEGFR (vascular endothelial growth factor receptor) is at a lot of pernicious cancer cells, surperficial high expression level (Deng Jingyu as malignant liver cell and incidence squamous epithelium cancer cells, He Sheng waits the effect of .VEGF in liver cancer, and world Chinese digests magazine, 2004,12 (2): 454-458); Endogenous agglutinin of blood is having higher [the Raz A of high metastatic malignant cell surface content to lung, Meromsky L, Lotan R, Deng. endogenous lectin is at the differential expression of normal cell, tumour cell and metastases cell surface, Cancer Research, in July, 1986,46 (7): 3667-3672].The mark that these cell surface molecules might take place as metastases at diagnosing tumor, judging prognosis, lapse to and estimate aspects such as curative effect and high risk population's follow-up observation, has bigger practical value.
Existing display technique of bacteriophage normally screens sublimed albumen, obtains oligopeptides or antibody with this albumen specific combination.We use display technique of bacteriophage pair cell surface antigen to screen on this basis, can obtain the oligopeptides molecule of pair cell surface specific combination by this method.Our scheme has overcome some problems in the cell screening in the past, mainly is cell surface complicated component and the unknown, cell screening non-specific bigger, and the background value height, and also transfer and non-metastatic tumour iuntercellular cell surface difference are little.
Summary of the invention
The objective of the invention is to overcome the prior art above shortcomings, provide a kind of and metastases cell-specific bonded polypeptide and application thereof.
Because the surface of intact cell has antigenic components such as a large amount of carbohydrates, albumen relevant with metastases, so they are potential tumor markerses.The present invention uses tumor in situ cell and metastases clone, and phage library is carried out differential screening, thus obtain can with metastases clone specificity bonded 12 peptides.
The present invention uses SW480 (tumor in situ clone) and SW620 (metastases clone) differential screening phage peptide library, obtains optionally in conjunction with 12 peptides of metastases cell, and its aminoacid sequence is as follows:
Leu-Pro-Trp-Lys-Glu-Pro-Tyr-Tyr-Leu-Met-Pro-Pro。
At low transfer cell line MCF7 (ATCC preserving number: HTB-22) and T47D (ATCC preserving number: HTB-133), and high-transfer cell is a MD-MB-231 (ATCC preserving number: HTB-26) and MD-MB-435 (ATCC preserving number: HTB-129) etc. in 4 clone, confirmed that the transfer ability of above-mentioned 12 peptides and tumour is proportionate.
The invention has the beneficial effects as follows: 12 peptides provided by the invention can be used as the mark of metastases diagnosis, and can be used as the precursor that exploitation suppresses tumor metastasis medicine.
Description of drawings
Fig. 1. be that each is taken turns the rate of recovery of SW620 cell-specific in conjunction with phage in the phage display,
Fig. 2. be the phage that obtains through four-wheel screening and the comparison of original storehouse phage and SW620 and SW480 cell binding ability,
Fig. 3. be that 105 phage mono-clonals are all made ELISA with SW480 and SW620 cell and blank well and detected,
Fig. 4. be the binding ability of the phage of expression four peptide species that obtain after the order-checking to SW480, SW620, MCF7, T47D, MD-MB-231 and MD-MB-435,
Fig. 5. be that scratch test detects the influence of 12 peptides to metastases cell SW620 motor capacity.
Embodiment
Embodiment 1: through four-wheel screening obtain can with the recombinant phage of SW620 cell surface selective binding
The first round: with RPMI1640 substratum powder (Gibico company) 10.4g, sodium bicarbonate 2.0g is dissolved in the 800ml distilled water, add 10ml 1mol/L HEPES solution, again with distilled water with the cumulative volume constant volume to 1000ml, 4 ℃ of preservations after the 0.22 μ m membrane filtration degerming; It is two anti-to add foetal calf serum (FBS is available from Tianjin hemopathy institute) and penicillin-Streptomycin sulphate in above-mentioned substratum, makes its content reach 10% and 1%, 4 ℃ of preservation respectively; Above-mentioned substratum 2ml is joined in each hole of 6 orifice plates, (the ATCC preserving number: CCL-228), making cell density is 10 to insert the SW620 cell 6Individual/hole, in carbon dioxide cell incubator, cultivated about 48 hours; Discard substratum, cell with 1 * PBS washing (10 * PBS: sodium-chlor 80.0g, Repone K 2.0g, Sodium phosphate dibasic 14.4g, SODIUM PHOSPHATE, MONOBASIC 2.4g is dissolved in the 800ml deionized water, adjust pH to 7.4 is settled to 1 liter with deionized water again.1 * PBS: with above-mentioned 10 * PBS with 10 times of deionized water dilutions, before using 121 ℃ of following autoclavings 20 minutes); Add 5ml confining liquid (PBS that contains 10mg/ml BSA) incubated at room 1 hour; Meanwhile, with 1 * 10 11Original library phage (12 peptide M13 phage display library test kits, available from New England Biolabs company) at random joins in the 2ml confining liquid, 4 ℃ of sealings 1 hour; Discard the confining liquid in the above-mentioned cell hole, the phage solution that sealing is good joins in the hole incubated at room 2 hours; Discard hole pnagus medius solution, add PBST (PBS that contains 0.1%Tween) and wash 10 times, PBS washes twice, adds 1ml elutriant (0.2mol/LGlycine-Cl, pH 2.2) then, wash-out 10 minutes; Take out supernatant, add immediately 150 μ l neutralizers (1mol/L Tris-Cl, pH9.0); Get 50 μ l wash-out bacteriophages, measure titre (concrete grammar is seen the rear portion of present embodiment) with the agar lay-up method; Simultaneously phage is added among the intestinal bacteria ER2738 cultivate mid-log phase [F ' lacI qΔ (lacZ) M15 proA +B +Zzf::Tn10 (Tet R)/fhuA2 supE thi Δ (lac-proAB) Δ (hsdMS-mcrB) 5 (r k -m k -McrBC -) bacterial strain is kept in the LB substratum that contains 50% glycerine, is stored in-70 ℃], 250 rev/mins, cultivate amplification 4.5 hours for 37 ℃; 10000 rev/mins of amplified productions are centrifugal 10 minutes; Supernatant with 80% is drawn onto in the new centrifuge tube, adds the PEG solution of 1/6 supernatant volume, and 4 ℃ of precipitations are spent the night; 10000 rev/mins centrifugal 15 minutes, abandon supernatant; With the resuspended precipitation of 200 μ l PBS, 10000 rev/mins centrifugal 5 minutes (remove remaining bacteria precipitation), supernatant is transferred in the new 0.5mL centrifuge tube, the phage that Here it is has increased.Measure phage titre with the agar lay-up method.
Second takes turns: respectively with SW480 (the ATCC preserving number: CCL-228) and the SW620 cell with 10 6Cells/well is taped against in 6 orifice plates, cultivates 2 days; (titre is about 1 * 10 to the phage of increasing according to the method adding first round of the first round 10), combine incubated at room 1 hour with the SW480 cell; Take out hole pnagus medius solution, join in another SW480 hole incubated at room 1 hour; Take out the phage solution in second SW480 cell cultures hole, join in the SW620 hole, incubated at room 2 hours; Wash-out, the step such as amplification and the first round are identical; With carry out the screening of third round and four-wheel with quadrat method, each is taken turns the used phage quantity of screening and is about 1 * 10 10
The agar lay-up method is measured the concrete enforcement of titre:
The single bacterium colony of inoculation intestinal bacteria ER2738 contains to 5ml in the LB substratum of tetracycline hydrochloride to be cultivated, to OD 600Be about 0.5; Get a test tube that 3ml upper strata solid LB substratum (the LB substratum that contains 0.7% agar powder) is housed, place boiling water bath to be heated to fully and melt, place 45 ℃ of water-baths to be incubated again; Get 10 μ l phage solution to be measured, in 1 * PBS, carry out 10 times of serial dilutions, to about 10 μ l phage solutions, contain 100 phages; Get 200 μ l intestinal bacteria ER2738 nutrient solutions, in nutrient solution, add 10 μ l and dilute good phage solution, at room temperature left standstill 5 minutes behind the mixing that vibrates gently; The intestinal bacteria nutrient solution that is added with phage is joined in the 3ml solid LB substratum of above-mentioned 45 ℃ of insulations, be poured on behind the mixing on the IPTG/X-gal flat board of 37 ℃ of pre-incubations, after treating that upper strata solid LB substratum solidifies fully, flat board is inverted in overnight incubation in 37 ℃ of incubators.
Check flat board in second day, the blue plaque on the flat board is counted, correspondingly multiply by extent of dilution again, just obtain contained phage pfu (plaque forming unit) quantity of per 10 μ l in the prophage solution.
The result: carry out 4 and take turns the enrichment screening, every ratio of taking turns the phagocytosis scale of construction that elutes from the SW620 cell surface and the amount that adds phage raises gradually, has realized specific enrichment (seeing Table 1).Elution amount/the add-on of four-wheel is represented with Fig. 1 in the table 1.
Among Fig. 1: the phagocytosis scale of construction of the phagocytosis scale of construction/adding of the rate of recovery=wash-out, the unit of Y-axis is * 10 -6
Table 1 screening is to SW620 specificity bonded phage
Figure S2008101286335D00041
Embodiment 2: phage is to the mensuration of SW480 and SW620 binding ability
SW480 and SW620 are respectively with 10 6Cells/well is taped against in 6 orifice plates, cultivates about 48 hours (substratum RPMI1640,10%FBS for 37 ℃ in carbon dioxide cell incubator, 1% penicillin-Streptomycin sulphate is two anti-), discard substratum, the PBS washing added confining liquid (PBS that contains 10mg/ml BSA) incubated at room 1 hour; Simultaneously, with 1 * 10 11The amplification of pfu four-wheel obtains phage and joins in the 2ml confining liquid, and 4 ℃ were sealed 1 hour; , discard confining liquid in the cell cultures hole, (titre is about 1 * 10 respectively to add the phage that 2ml seals in SW480 and SW620 hole 11), incubated at room 2 hours; Discard phage, the PBS washed twice is used in PBST (PBS that contains 0.1%Tween) washing 10 times again, and wash-out is measured titre separately; Original library phage compares, and also carries out above-mentioned test simultaneously.The phage that four-wheel obtains mixes the storehouse and the more original phage library of SW620 binding ability has improved 100 times, it is 100 times of itself and SW480 bonded that phage that four-wheel obtains mixes storehouse and SW620 binding ability, promptly the phage library that obtains of four-wheel can specificity combine with SW620, sees Fig. 2.Among Fig. 2:
Figure S2008101286335D00051
The phage number that expression elutes from the SW480 cell;
represents the phage number that elutes from the SW620 cell;
1: the expression contrast is to add respectively among SW620 and the SW480 with original library phage;
2: expression adds respectively among SW620 and the SW480 with the phage of four-wheel amplification.
Embodiment 3: the separation preparation of monoclonal phage
Mono-clonal phage after 105 screenings 4 of picking are taken turns at random joins among the intestinal bacteria ER2738 of mid-log phase, and 37 ℃, shaking table (250 rev/mins) was cultivated 4.5~5 hours; Centrifugal 10 minutes of 10000 rev/mins of amplified productions are got the PEG/NaCl solution that supernatant adds 1/6 volume, and 4 ℃ of precipitations are spent the night; 10000 rev/mins centrifugal 15 minutes, abandon supernatant; With the resuspended precipitation of 200 μ l PBS, 10000 rev/mins centrifugal 5 minutes, remove remaining bacteria precipitation; Phage titre with in the agar lay-up method mensuration supernatant liquor adds equal-volume glycerine, is stored in-20 ℃.
With 105 phage mono-clonals intact cell SW480 or SW620 are carried out the ELISA detection.In 96 orifice plates, add 10 respectively 5SW480 or SW620 cells/well are cultivated adding 200 μ l confining liquids [5% (w/v) BSA is dissolved in PBS] in every two days later hole, seal 1 hour; Add mono-clonal phage 1 * 10 10, every hole 50 μ l were hatched 2 hours; PBST washing 5 times detects the bonded phage particle with the anti-M13 antibody of HRP-(Pharmacia Biotech company), and tetramino p-diaminodiphenyl (TMB) is substrate, develops the color about 5 minutes, adds 100 μ l H 2SO 4Stopped reaction.Measure the absorbance value of 450nm.Nearly all phage mono-clonal all shows the high associativity to the SW620 cell, and the associativity to the SW480 cell is lower simultaneously, sees Fig. 3.
Among Fig. 3: X-coordinate is represented different phage mono-clonals, and ordinate zou is represented average clean light absorption value;
represents the average clean light absorption value in SW620 hole;
■ represents the average clean light absorption value in SW480 hole.
Each phage mono-clonal all combines with SW480 and SW620 cell and blank well among Fig. 3.After the washing, with horseradish peroxidase connection M13 antibody and substrate TMB thereof the ELISA reaction is carried out in each hole, and detected OD 450The OD in SW620 or hole, SW480 place 450Value deducts corresponding blank well OD 450Value obtains its clean light absorption value.Each clone has been carried out two groups of detections, and data are two groups of mean values that detect on the figure.
Embodiment 4: the acquisition of the extraction of phage genome single stranded DNA and 12 peptide sequences
The sedimentary phage of PEG is resuspended in 200 μ l sodium iodide damping fluid (10mmol/L Tris-HCl, pH8.0,1mmol/L EDTA, 4mol/L NaI, the room temperature lucifuge is stored) in, add 500 μ l dehydrated alcohols, incubated at room 10 minutes, 10000 rev/mins centrifugal 10 minutes, abandon supernatant, wash precipitation with 70% ethanol, 10000 rev/mins centrifugal 10 minutes, abandon supernatant, resuspended being deposited in the 30 l deionized waters.With-96 gIII primers (5 '-CCCTCATAGTTAGCGTAACG-3 ', New England Biolabs is dodecapeptide phage display library product at random) order-checking.Sequencing result obtains peptide sequence with Prime Primier software translation.4 kinds of different sequencing results are arranged, so corresponding 4 kinds of 12 different peptide sequences.They are:
Leu-Pro-Trp-Lys-Glu-Pro-Tyr-Tyr-Leu-Met-Pro-Pro (1)
Ser-Pro-Trp-Ser-Glu-Pro-Ala-Tyr-Tyr-Leu-Ala-Pro (2)
Val-Pro-Trp-Met-Glu-Pro-Ala-Tyr-Gln-Arg-Phe-Leu (3)
Ser-Val-Ser-Val-Gly-Met-Lys-Pro-Ser-Pro-Arg-Pro (4)
Embodiment 5: it is right that 12 peptides are carried out multiple ratio
Use multiple ratio software Clustal W is compared to 4 the 12 peptide prefaces that embodiment 4 obtains, find that the similarity of 12 peptide sequences (1) (2) (3) is very high, the sequence of their high conservative is: Pro-Trp-X 1-Glu-Pro-X 2-Tyr, wherein X 1And X 2Represent any amino acid, this conserved sequence plays a crucial role to the 26S Proteasome Structure and Function of keeping 12 peptides.
Embodiment 6: intact cell is carried out ELISA measure
In 96 orifice plates, add 10 respectively 5SW480 or SW620 cells/well were cultivated two days; 5 * 10 4MCF7, T47D, MD-MB-231 or MD-MB-435 cells/well were cultivated one day.Add 200 μ l confining liquids [5% (w/v) BSA is dissolved in PBS] in every hole, sealed 1 hour.The phage 1 * 10 that adds single clone 10Hatched 2 hours in 50 μ l/ holes.Detect the bonded phage particle with the anti-M13 antibody of HRP-(Pharmacia Biotech company) after PBST washs 5 times, tetramino p-diaminodiphenyl (TMB) is substrate, develops the color about 5 minutes, adds 100 μ l H 2SO 4Stopped reaction.Measure the absorbance value of 450nm.Replace contrast for each clone is not all had specific original library phage.Four peptide species that obtain of order-checking have high combination to the tumour cell of multiple high transfer ability, and to the tumour cell of multiple low transfer/do not shift in conjunction with very weak.Confirm that further 12 peptide sequences of the present invention have broad spectrum to the specific combination of metastatic tumour cell, see Fig. 4.
Among Fig. 4:
Figure S2008101286335D00071
Expression express polypeptide 1 phage is to the combination of various clones
Figure S2008101286335D00072
Expression express polypeptide 2 phages are to the combination of various clones
Figure S2008101286335D00073
Expression express polypeptide 3 phages are to the combination of various clones
Figure S2008101286335D00074
Expression express polypeptide 4 phages are to the combination of various clones
Figure S2008101286335D00075
Represent of the combination of original library phage to various clones
Embodiment 7: scratch test proves the influence of 12 peptides to the tumour cell motor capacity
Bottom surface in 24 each hole of orifice plate mark (as using the pin mark signature, point of crossing and cross can be used in the follow-up test the location relatively, perhaps with the marking pen location of marking).In each hole of 24 orifice plates, add 3 * 10 respectively 5The SW620 cell is cultivated the floorage that covered each hole of 90-100% in 2-3 days to the monolayer that forms.On monolayer cell, cross location dot-dash straight line cut with yellow suction nozzle point.With the substratum cell crossed out of flush away gently.Every hole adds 10 7The phage of express polypeptide 1,12 peptide sequences of this phage expression are Leu-Pro-Trp-Lys-Glu-Pro-Tyr-Tyr-Leu-Met-Pro-Pro.Add 10 7The metastatic tumour cell there is not the original storehouse of specificity bonded phage in contrast.Cultivate with serum free medium (substratum RPMI1640,1% penicillin-Streptomycin sulphate two anti-), and took pictures at 0,5 and 24 hour (the zoom multiple is 40).With the doubling of the image of the mark at the bottom of 24 orifice plates with same hole different time points, observe the motor capacity of tumour cell, prove that this 12 peptides in the external motor capacity that can suppress high metastatic tumour cell, see Fig. 5.
Among Fig. 5: a top line display adds original library phage in the SW620 cell, below delegation's graphical representation in SW620, added the phage of specific combination metastatic tumour cell, different photo opporunity behind the time representation cut below every row.
SEQUENCE?LISTING
<110〉Nankai University
<120〉with metastases cell-specific bonded polypeptide and application thereof
<160>4
<210>1
<211>12
<212>PRT
<213〉artificial sequence
<220>
<221>PEPTIDE
<222>(1)..(12)
<223>
<400>1
Leu?Pro?Trp?Lys?Glu?Pro?Tyr?Tyr?Leu?Met?Pro?Pro
1 5 10
<210>2
<211>12
<212>PRT
<213〉artificial sequence
<220>
<221>PEPTIDE
<222>(1)..(12)
<223>
<400>2
Ser?Pro?Trp?Ser?Glu?Pro?Ala?Tyr?Tyr?Leu?Ala?Pro
1 5 10
<210>3
<211>12
<212>PRT
<213〉artificial sequence
<220>
<221>PEPTIDE
<222>(1)..(12)
<223>
<400>3
Val?Pro?Trp?Met?Glu?Pro?Ala?Trp?Gln?Arg?Phe?Leu
1 5 10
<210>4
<211>12
<212>PRT
<213〉artificial sequence
<220>
<221>PEPTIDE
<222>(1)..(12)
<223>
<400>4
Ser?Val?Ser?Val?Gly?Met?Lys?Pro?Ser?Pro?Arg?Pro
1 5 10

Claims (2)

1. one kind is detected application in the metastases reagent with metastases cell-specific bonded polypeptide in preparation, and described amino acid sequence of polypeptide is as follows: Leu-Pro-Trp-Lys-Glu-Pro-Tyr-Tyr-Leu-Met-Pro-Pro.
2. one kind is suppressed application in the tumor metastasis medicine with metastases cell-specific bonded polypeptide in exploitation, and described amino acid sequence of polypeptide is as follows: Leu-Pro-Trp-Lys-Glu-Pro-Tyr-Tyr-Leu-Met-Pro-Pro.
CN2008101286335A 2005-09-27 2005-09-27 Polypeptide having specific combination with neoplasm metastasis cell and uses thereof Expired - Fee Related CN101319008B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2008101286335A CN101319008B (en) 2005-09-27 2005-09-27 Polypeptide having specific combination with neoplasm metastasis cell and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2008101286335A CN101319008B (en) 2005-09-27 2005-09-27 Polypeptide having specific combination with neoplasm metastasis cell and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100152378A Division CN100486991C (en) 2005-09-27 2005-09-27 Screening and authentication of polypeptide binding specificly to tumour tranferring cell

Publications (2)

Publication Number Publication Date
CN101319008A CN101319008A (en) 2008-12-10
CN101319008B true CN101319008B (en) 2010-12-01

Family

ID=40179306

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008101286335A Expired - Fee Related CN101319008B (en) 2005-09-27 2005-09-27 Polypeptide having specific combination with neoplasm metastasis cell and uses thereof

Country Status (1)

Country Link
CN (1) CN101319008B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103012561B (en) * 2012-12-26 2014-06-25 首都医科大学附属北京朝阳医院 Small peptide for tumor targeted diagnosis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136082A1 (en) * 2000-03-24 2001-09-26 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Local drug delivery
US6344443B1 (en) * 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
CN1502625A (en) * 2002-11-20 2004-06-09 中国人民解放军军事医学科学院放射医 Oligopeptide suppressor of matrix metalloprotease 2
WO2005014823A2 (en) * 2003-08-05 2005-02-17 Wisconsin Alumni Research Foundation Targeted carrier fusions for delivery of chemotherapeutic agents
WO2005039616A1 (en) * 2003-10-29 2005-05-06 Ramot At Tel Aviv University Ltd. Angiogenic peptides and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344443B1 (en) * 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
EP1136082A1 (en) * 2000-03-24 2001-09-26 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Local drug delivery
CN1502625A (en) * 2002-11-20 2004-06-09 中国人民解放军军事医学科学院放射医 Oligopeptide suppressor of matrix metalloprotease 2
WO2005014823A2 (en) * 2003-08-05 2005-02-17 Wisconsin Alumni Research Foundation Targeted carrier fusions for delivery of chemotherapeutic agents
WO2005039616A1 (en) * 2003-10-29 2005-05-06 Ramot At Tel Aviv University Ltd. Angiogenic peptides and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
温再和,等,.抗癌活性肽抑制肿瘤生长和转移的研究进展.内蒙古医学杂志.2005,37(1),34-36.
温再和等.抗癌活性肽抑制肿瘤生长和转移的研究进展.内蒙古医学杂志.2005,37(1),34-36. *

Also Published As

Publication number Publication date
CN101319008A (en) 2008-12-10

Similar Documents

Publication Publication Date Title
CN100486991C (en) Screening and authentication of polypeptide binding specificly to tumour tranferring cell
CN103421115B (en) CD38 nanometer antibody and application
CN102532272A (en) Polypeptide specifically combined with HepG2 cell surface
CN106831981B (en) A kind of single domain antibody peptide backbone and preparation method thereof
CN104233474A (en) Synthetic phage display nano antibody library and application thereof
CN103804493A (en) Heavy chain antibody VHH for influenza a virus H1N1 and application thereof
CN103396482B (en) A kind of prealbumin nano antibody, its coded sequence and application
Addadi et al. Molecular recognition at the interface between crystals and biology: generation, manifestation and detection of chirality at crystal surfaces
CN102936598B (en) Coding gene of anti-Cry1Ac toxin single-chain variable fragments (scFv) and immuno-polymerase chain reaction (PCR) detection method
CN101319008B (en) Polypeptide having specific combination with neoplasm metastasis cell and uses thereof
CN104745588A (en) Specific nucleic acid aptamer for recognizing streptomycin and application of nucleic acid aptamer to streptomycin detection
CN109517036B (en) Lung carcinoma cell specific binding polypeptide and preparation method thereof
CN101412750B (en) Bursin specific binding peptide and screening method thereof
CN103936852B (en) Specificity is for the nano antibody of A type H3N2 influenza virus and the application in diagnosis thereof
Sukul et al. A water-soluble metal–organic complex array as a multinuclear heterometallic peptide amphiphile that shows unconventional anion dependency in its self-assembly
CN103848895B (en) The linear dodecapeptide antigenic epitope of aflatoxin B1 and its application
CN104530194B (en) Antigenic epitope for ochratoxin A and its application
CN103044526A (en) Antigenic mimic epitope of vardenafil and application thereof
CN103044527A (en) Antigenic mimic epitope of gentamycin and application thereof
CN104327166B (en) The dodecapeptide antigenic epitope of ochratoxin A and its application
TWI642685B (en) Novel peptide and application thereof
CN104130313B (en) Synthetic bursin BPP-II specific binding peptides and application thereof
CN101113164B (en) 12 peptide specifically combined with tumor metastasis related protein PRL-3 and uses thereof
CN104530195B (en) Simulate antigenic epitope and its application of ochratoxin A
CN103848898B (en) The antigenic epitope Ph3 of dihydroxyphenyl propane and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101201

Termination date: 20110927